FDMT
NASDAQ · Biotechnology
4D Molecular Therapeutics In
$11.60
+1.18 (+11.32%)
Open$10.22
Previous Close$10.42
Day High$12.18
Day Low$10.22
52W High$12.34
52W Low$3.68
Volume—
Avg Volume737.0K
Market Cap504.99M
P/E Ratio—
EPS$-2.70
SectorBiotechnology
Analyst Ratings
Strong Buy
17 analysts
Price Target
+82.0% upside
Current
$11.60
$11.60
Target
$21.11
$21.11
$12.84
$21.11 avg
$26.25
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 84.12M | 286.9K | 228.58M |
| Net Income | -138,319,980 | -1,099,890,361 | -57,732,834 |
| Profit Margin | -164.4% | -413,039.5% | -25.3% |
| EBITDA | -152,874,861 | -1,322,641,633 | -107,016,126 |
| Free Cash Flow | — | — | -89,291,698 |
| Rev Growth | +200.8% | -87.3% | +10.3% |
| Debt/Equity | — | — | 0.12 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $234.89 | +0.06% | 105.2 | 382.49B |
| AMGN | Amgen Inc | $351.43 | +1.27% | 23.4 | 182.21B |
| GILD | Gilead Sciences Inc | $125.16 | +0.09% | 16.7 | 153.66B |
| VRTX | Vertex Pharmaceuticals Inc | $475.20 | +1.45% | 26.4 | 114.63B |
| REGN | Regeneron Pharmaceuticals | $623.43 | +0.87% | 14.5 | 63.95B |
| ALNY | Alnylam Pharmaceuticals Inc | $294.06 | +2.04% | 64.3 | 37.13B |